title: In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
abstract: Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n=200 strains), nonmucoid P. aeruginosa (n=200), and Burkholderia cepacia complex (n=200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 microg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.
authors.affiliation: Department of Pediatrics, Columbia University, 622 West 168th St., PH4W-470, New York, NY 10032, USA.
authors.forename: Yunhua
authors.initials: Y
authors.lastname: Chen
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Garber
authors.forename: Qiuqu
authors.initials: Q
authors.lastname: Zhao
authors.forename: Yigong
authors.initials: Y
authors.lastname: Ge
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Wikler
authors.forename: Koné
authors.initials: K
authors.lastname: Kaniga
authors.forename: Lisa
authors.initials: L
authors.lastname: Saiman
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019121:Burkholderia Infections / Q000382:microbiology; D042602:Burkholderia cepacia complex / Q000187:drug effects* / Q000302:isolation & purification; D015780:Carbapenems / Q000494:pharmacology*; D003550:Cystic Fibrosis / Q000382:microbiology*; D000077726:Doripenem; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000077726:Doripenem